FINVX | LYRNX | FINVX / LYRNX | |
Total Expense Ratio | 0.01 | 1.24 | 1% |
Annual Report Gross Expense Ratio | 0.01 | 5.99 | 0% |
Fund Existence | 16 years | 5 years | - |
Gain YTD | 25.839 | 25.090 | 103% |
Front Load | N/A | N/A | - |
Min. Initial Investment | 0 | 2500 | - |
Min. Initial Investment IRA | N/A | N/A | - |
Net Assets | 15.9B | 2.51M | 633,971% |
Annual Yield % from dividends | 3.73 | 2.67 | 140% |
Returns for 1 year | 23.93 | 20.71 | 116% |
Returns for 3 years | 71.34 | 46.97 | 152% |
Returns for 5 years | 117.63 | 70.79 | 166% |
Returns for 10 years | 82.21 | N/A | - |
1 Day | |||
---|---|---|---|
ETFs / NAME | Price $ | Chg $ | Chg % |
PTNQ | 69.87 | 0.09 | +0.13% |
Pacer Trendpilot™ 100 ETF | |||
NUMG | 47.43 | -0.24 | -0.50% |
Nuveen ESG Mid-Cap Growth ETF | |||
SPHQ | 69.96 | -0.57 | -0.81% |
Invesco S&P 500® Quality ETF | |||
RSPM | 32.10 | -0.33 | -1.02% |
Invesco S&P 500® Equal Weight Matrls ETF | |||
BIB | 45.94 | -0.60 | -1.29% |
ProShares Ultra Nasdaq Biotechnology |